A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine–Experienced Adults 50 Years of Age or Older (STRIDE-6)
2024

Study of V116 Pneumococcal Vaccine in Older Adults

Sample size: 717 publication Evidence: high

Author Information

Author(s): Scott Paul, Haranaka Miwa, Choi Jung Hyun, Stacey Helen, Dionne Marc, Greenberg David, Grijalva Carlos G, Orenstein Walter A, Fernsler Doreen, Gallagher Nancy, Zeng Tiantian, Li Jianing, Platt Heather L, Chapman Timothy J, Davis Karyn, Dionne Marc, Dzongowski Peter, Girard Ginette, Tellier Guy, Tytus Richard, Jaffuel Sylvain, Nicolas Jean-Francois, Ami Eytan Ben, Bendayan Daniele, Caraco Yoseph, Chowers Michal, Darawsha Mahmud, Peer Avivit, Blasi Francesco Bruno, Castagna Antonella, Costantino Claudio, Martinelli Domenico, Haranaka Miwa, Yono Makoto, Choi Jung Hyun, Choi Won Suk, Lee Dong-Gun, Lee Jacob, Shi Hyejin, Song Joon Young, De luiz Martinez Gustavo, Echave-Sustaeta Maria-Tome Jose Maria, Aumatell Cristina Masuet, Perez Silvia Narejos, Vilella i Morato Anna, Huang Kuo-Chin, Yang Yi-Ching, Butuk David J, Cardona Jose Francisco, Daboul Nizar, Fiel Thomas, Fraser Neil J, Freeman George Hartley, Geller Steven A, Harper Charles Harold, Johnston William Henry Jr., Lenzmeier Thomas C, Pelayo Enrique, Porterfield Laura, Rigonan Kathryn R, Rosen Jeffrey Bruce, Stacey Helen L

Primary Institution: Merck & Co., Inc.

Hypothesis

Does the V116 vaccine provide safety, tolerability, and immunogenicity in pneumococcal vaccine-experienced adults aged 50 and older?

Conclusion

V116 is well tolerated and generates immune responses to all vaccine serotypes in adults previously vaccinated with pneumococcal vaccines.

Supporting Evidence

  • V116 was immunogenic across all cohorts, generating immune responses to all 21 serotypes.
  • The safety profile of V116 was comparable to currently licensed pneumococcal vaccines.
  • Participants with preexisting conditions showed similar immune responses to those without.
  • V116 includes 8 serotypes not covered by any other licensed vaccine, addressing unmet medical needs.

Takeaway

The V116 vaccine helps older adults fight off pneumonia germs and is safe to use.

Methodology

This phase 3 study involved 717 adults aged 50 and older, divided into three cohorts based on their previous pneumococcal vaccination history, and assessed safety and immune response after vaccination with V116.

Limitations

Cohort 3 was unblinded, which could have affected safety reporting.

Participant Demographics

The majority of participants were female and White, non-Hispanic, with 70.6% aged 65 or older.

Digital Object Identifier (DOI)

10.1093/cid/ciae383

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication